Ecubectedin - PharmaMar
Alternative Names: PM-14Latest Information Update: 02 Aug 2024
At a glance
- Originator PharmaMar
- Class Acetates; Antineoplastics; Aza compounds; Heterocyclic compounds with 4 or more rings; Indoles; Small molecules; Spiro compounds
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Soft tissue sarcoma
- Phase I Prostate cancer
Most Recent Events
- 02 Aug 2024 Phase-I development in Solid-tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) ongoing in Spain and France (IV, Infusion)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in France (IV, Infusion)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Spain (IV, Infusion)